EFFICACY AND SAFETY OF ETANERCEPT TREATMENT IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS. THE RESULTS OF AN OPEN PROSPECTIVE STUDY ON THE BASIS OF THE SCIENTIFIC CENTER OF CHILDREN'S HEALTH (MOSCOW)

Background: Addition of genetically engineered biological agents in the paradigm of juvenile idiopathic arthritis (JIA) treatment significantly increased the efficacy of the antirheumatic therapy in patients with this severe chronic disease.

Objective. Our aim was to assess the efficacy and safety of etanercept treatment in patients with JIA without systemic manifestations.

Methods. The open prospective study included patients with JIA without systemic manifestations treated with etanercept.

The treatment was carried out on the basis of the rheumatological department of the Scientific Center of Children's Health (Moscow) in the period from December 2009 to August 2014. To assess the therapy efficacy in a year, we used the improvement definition for pediatric patients of the American College of Rheumatology (ACR_pedi) 30, 50, 70, and 90. Reaching the stage of inactive disease/remission were recorded under С. Wallace criteria and threshold value of the JIA activity index (JADAS71).

Results. Totally, the study included 197 patients. After 1 year from the treatment beginning, the ACR_pedi30 improvement was reported in 179 (90.9%) patients, ACR_pedi50 — in 177 (89.8%), ACR_pedi70 — in 168 (85.3%), and ACR_pedi90 — in 135 (68.5%). The stage of inactive disease/remission under C. Wallace criteria was ascertained in 132 (67.0%), under JADAS71 index — in 92 (46.7%) patients.

Conclusion. After 1 year of etanercept treatment, the stage of inactive disease/remission and the improvement under ACR_pedi90 criterion have been reported in almost half (45.7%) of patients with juvenile idiopathic arthritis without systemic manifestations. The predictors of a high response to etanercept were a short disease duration, less number of used disease-modifying antirheumatic drugs, and a low level of C-reactive protein in the blood serum before etanercept prescription.

1. Wallace CA, Giannini EH, Huang B, et al. American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011,63(7):929–36. doi: 10.1002/acr.20497.

2. Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. JRA Criteria Subcommittee of the Diagnostic and Therapeutic Criteria Com mittee of the American Rheumatism Section of the Arthritis Foundation. Arthritis Rheum. 1977,20(Suppl):195–199.

3. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol. 1998,25:1991–1994.

4. Woo P, Wedderburn LR. Juvenile chronic arthritis. Lancet. 1998,351:969–973.

5. Overall incidence in children in Russia (under age of 14 years) in 2014.

6. Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol. 2011,30(9):1163–72. doi: 10.1007/s10067-011-1720-7.

7. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003,48(4):1093–101. doi: 10.1002/art.10885.

8. Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013,65(10):2499–512. doi: 10.1002/art.38092.

9. van Dijkhuizen EH, Wulffraat NM. Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review. Ann Rheum Dis. 2015,74(11):1996–2005. doi: 10.1136/annrheumdis-2014-205265.

10. Otten MH, Prince FH, Armbrust W, et al. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis. JAMA. 2011,306(21):2340–7. doi: 10.1001/jama.2011.1671.

11. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011,63(4):465–82. doi: 10.1002/acr.20460.

12. Southwood TR, Foster HE, Davidson JE, et al. British Society for Adolescent and Paediatric Rheumatology Biologics and New Drugs Register. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology (Oxford). 2011,50(1):189–95. doi: 10.1093/rheumatology/keq308.

13. Romano M, Pontikaki I, Gattinara M, et al. Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients. Reumatismo. 2014,65(6):278–85. doi: 0.4081/reumatismo.2013.682.

14. Esbjornsson AC, Aalto K, Brostrom EW, et al. Nordic Study Group of Paediatric Rheumatology (NoSPeR). Ankle arthritis predicts polyarticular disease course and unfavourable outcome in children with juvenile idiopathic arthritis. Clin Exp Rheumatol.2015,33(5):751–7.

15. Kearsley-Fleet L, Davies R, Lunt M, et al. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. Rheumatology (Oxford). 2016,55(5):840–7. doi: 10.1093/rheumatology/kev434.

16. Solari N, Palmisani E, Consolaro A, et al. Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. J Rheumatol. 2013,40(2):192–200. doi: 10.3899/jrheum.120842.

17. Consolaro A, Bracciolini G, Ruperto N, et al. Paediatric Rheumatology International Trials Organization. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum. 2012,64(7):2366–74. doi: 10.1002/art.34373.

18. Geikowski T, Becker I, Horneff G. German BIKER Registry Collaborative Study Group. Predictors of response to etanercept in polyarticular-course juvenile idiopathic arthritis. Rheumatology (Oxford). 2014,53(7):1245–9. doi: 10.1093/rheumatology/ket490.

19. Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch natio nal register. Ann Rheum Dis. 2009,68(5):635–41. doi: 10.1136/ard.2007.087411.

20. Papsdorf V, Horneff G. Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis. Rheumatology (Oxford). 2011,50(1):214–21. doi: 10.1093/rheumatology/keq292.

21. Giannini EH, Ilowite NT, Lovell DJ, Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009,60(9):2794–804. doi: 10.1002/art.24777.